Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 1Recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Other hematologic neoplasm 1

Conditions

Lymphoma, Large B-Cell, Diffuse 14Lymphoma, Non-Hodgkin 7Lymphoma, B-Cell 5Lymphoma 3Recurrence 2Lymphoma, Follicular 2Lymphoma, B-Cell, Marginal Zone 2Hodgkin Disease 2Burkitt Lymphoma 2Neoplasms 1Lymphoma, Mantle-Cell 1Leukemia, Hairy Cell 1Hematologic Neoplasms 1

Interventions

Cyclophosphamide 27fludarabine 19Dexamethasone 18pembrolizumab 12Rituximab 12Etoposide 11venetoclax 10pomalidomide 9Gemcitabine 9Lenalidomide 8fludarabine phosphate 7daratumumab 7Bortezomib 7glofitamab 6carfilzomib 6Vincristine 6obinutuzumab 5Temozolomide 5Prednisone 5Nivolumab 5Immunotherapy, Adoptive 5Doxorubicin 5Cytarabine 5Cisplatin 5Calcium Dobesilate 5selinexor 4cemiplimab 4Carboplatin 4Azacitidine 4zanubrutinib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recurrence × polatuzumab vedotin × 90 days × Clear all
NCT05283720 2026-06-02

A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma

Genmab

Phase 2 Recruiting
496 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Hairy Cell, Lymphoma, Non-Hodgkin, Neoplasms, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT05498220 2026-04-16

Polatuzumab Vedotin With R-GDP in Relapsed/Refractory Diffuse Large B-cell Lymphoma

UNC Lineberger Comprehensive Cancer Center

Phase 2 Terminated
5 enrolled 13 charts
Lymphoid

Recurrence, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡